Celsion Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Celsion stock.
View analyst ratings for Celsion or view top-rated stocks.

2 analysts have issued twelve-month price targets for Celsion's shares. Their CLSN stock forecasts range from $16.00 to $16.00. On average, they expect Celsion's share price to reach $16.00 in the next year. This suggests a possible upside of 751.1% from the stock's current price.
View analysts' price targets for Celsion or view top-rated stocks among Wall Street analysts.

Celsion's stock was trading at $8.10 at the start of the year. Since then, CLSN stock has decreased by 76.8% and is now trading at $1.88.
View the best growth stocks for 2022 here.

Celsion is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Celsion.

Celsion Co. (NASDAQ:CLSN) posted its earnings results on Monday, May, 16th. The biotechnology company reported ($1.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by $0.83. Celsion had a negative net margin of 5,110.80% and a negative trailing twelve-month return on equity of 45.34%. During the same period last year, the firm earned ($1.35) earnings per share.
View Celsion's earnings history.

Celsion's stock reverse split on the morning of Tuesday, March 1st 2022. The 1-15 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

Some companies that are related to Celsion include Angion Biomedica (ANGN), Zynerba Pharmaceuticals (ZYNE), Elite Pharmaceuticals (ELTP), Corvus Pharmaceuticals (CRVS), Tyme Technologies (TYME), Athenex (ATNX), Galecto (GLTO), SELLAS Life Sciences Group (SLS), Aptorum Group (APM), Processa Pharmaceuticals (PCSA), Vaccinex (VCNX), Chemomab Therapeutics (CMMB), RedHill Biopharma (RDHL), Novan (NOVN) and Hepion Pharmaceuticals (HEPA).
View all of CLSN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Celsion investors own include Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Novan (NOVN), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), Agenus (AGEN) and CBL & Associates Properties (CBL).

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLSN stock can currently be purchased for approximately $1.88.

Celsion (NASDAQ:CLSN) has a market capitalization of $13.35 million and generates $500 thousand in revenue each year.

Celsion employs 27 workers across the globe.

Celsion was founded in 1982.

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The official website for Celsion is www.celsion.com. The biotechnology company can be reached via phone at (609) 896-9100, via email at [email protected], or via fax at 609-896-2200.